News

02 Nov 2017

Incentives, IP and smaller companies – the story of TiGenix

How TiGenix wants to change patients’ lives by improving health outcomes TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced Belgian biopharmaceutical SME with operations in Madrid, S...

Read more
24 Oct 2017

Incentives, IP and smaller companies – the story of ProAxsis

How ProAxsis helps to change patients’ lives by improving diagnostics ProAxsis Limited is a spin out from Queen’s University of Belfast, and based in Belfast, Ireland. Since its foundation...

Read more
18 Oct 2017

Incentives, IP and smaller companies – the story of CureVac

Infographic - Case Story Curevac How CureVac helps to change patients’ lives CureVac, a biopharmaceutical company headquartered in Tübingen, Germany, has grown from three original founde...

Read more
13 Oct 2017

6th EBE Annual Regulatory Conference “Realising the potential of advanced therapies for patients”

5 December 2017,  CCT South Quay Venue – Thames Quay, 193 Marsh Wall, London, E14 9SG, United Kingdom  Draft Agenda Register  Ten years after adoption of the EU regulation on advanc...

Read more
10 Oct 2017

EBE and EFPIA call on the EU Commission and Member States to improve transparency on Hospital Exemptions for Advanced Therapies

“Therapies for the future - Exploring solutions for innovative treatments in Europe” will take place at the European Parliament  on 11 October 2017. In advance of this significant discussion...

Read more
01 Oct 2017

Eduardo Bravo discusses the importance of pharmaceutical incentives to SMEs in the Parliament Magazine

An article written by Eduardo Bravo, CEO TiGenix and EBE President on 28 September 2017, and published in the Parliament Magazine  Incentives, particularly intellectual property (IP) protecti...

Read more
27 Sep 2017

ARM, EBE, EFPIA and EuropaBio jointly publish a series of proposals to streamline requirements and accelerate approvals of clinical trials with new therapies that consist of or contain Genetically Modified Organisms (GMOs) in Europe

The Alliance for Regenerative Medicine (ARM), the European Biopharmaceutical Enterprises (EBE), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and EuropaBio jointly publish a series of proposals to streamline requirements and accelerate approvals of clinical trials with new therapies that consist of or contain Genetically Modified Organisms (GMOs) in Europe....

Read more
18 Sep 2017

EBE-EFPIA Set Out Policy Positions in Their Personalised Medicines Manifesto

The EBE-EFPIA Personalised Medicine Working Group have developed a Manifesto that aims to highlight policy elements that are considered essential to ensure that personalised medicines and their paired diagnostic tests, also called companion diagnostics, successfully reach patients....

Read more
13 Jun 2017

EBE Webinar: IP and its crucial role in bringing innovative medicines to patients

20 June 2017 from 16H30 - 17H30 CET Europe has good science and sound Intellectual Property (IP) policies in place. These IP policies and other incentive offered by legislation when medicines are developed play a critical role in companies corporate and product development strategies....

Read more
30 May 2017

Final Call ATMP Survey: Help improve product development and regulation

Response deadline: 30 June 2017 Advanced Therapy Medicinal Products (ATMPs) are medicinal products including gene therapies, somatic cell therapies and tissue engineered products. They are characterised by their innovative character. Despite considerable development activity in this dynamic field, a limited number of ATMPs have received Marketing Authorisation in the European Union. There is a growing urgency to understand which factors are associated with the advancement of ATMPs through the medicines life-cycle....

Read more
1 2 3 4 5 7